# Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer

> **NCT01876784** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 238 (actual)

## Conditions studied

- Differentiated Thyroid Cancer

## Interventions

- **DRUG:** Vandetanib (SAR390530)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01876784
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-17
- **Primary completion:** 2015-08-30
- **Final completion:** 2022-01-22
- **Target enrollment:** 238 (ACTUAL)
- **Last updated:** 2024-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01876784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01876784, "Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01876784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*